These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12742487)

  • 21. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined hyperlipidemia and hypertriglyceridemia in renal allograft recipients. Comparison with non-renal combined hyperlipidemic or hypertriglyceridemic patients and normal subjects.
    Somer JB; Abbott LK; Aitken JM; Elliott C
    Clin Chim Acta; 1979 Oct; 97(2-3):123-34. PubMed ID: 226288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III trial of Rapamune versus placebo in primary renal allograft recipients.
    Ponticelli C; MacDonald AS; Rajagopalan P; Sindhi R; Mathew T
    Transplant Proc; 2001 May; 33(3):2271-2. PubMed ID: 11377525
    [No Abstract]   [Full Text] [Related]  

  • 24. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
    Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
    Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M; Banasik M; Patrzalek D; Szyber P; Klinger M
    Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid disorders in renal transplant recipients.
    Ponticelli C; Barbi GL; Cantaluppi A; De Vecchi A; Annoni G; Donati C; Cecchettin M
    Nephron; 1978; 20(4):189-95. PubMed ID: 345139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperlipidemia in children: the role of uremia, steroids and cyclosporine therapy.
    Singh A; Tejani A
    Nephron; 1996; 74(3):529-35. PubMed ID: 8938676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
    Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
    Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of serum lipids, lipoproteins, and fibrinogen in patients with kidney transplantation and hemodialysis.
    Demirağ A; Moray G; Ozdemir N; Hizel N; Bilgin N; Haberal M
    Transplant Proc; 1998 Aug; 30(5):2052-3. PubMed ID: 9723389
    [No Abstract]   [Full Text] [Related]  

  • 33. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
    Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
    Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of different immunosuppressive therapies on the lipid pattern in kidney-transplanted rats.
    Lausada N; de Gómez Dumm Nelva T; Georgina L; Gisela C; Clemente R
    Transpl Int; 2005 May; 18(5):524-31. PubMed ID: 15819800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppression with sirolimus, cyclosporyne, and prednisone in renal transplantation.
    Gonzalez-Posada JM; Rodriguez AP; Pérez-Tamajón L; Hdez-Marrero D; Maceira B
    Transplant Proc; 2002 Feb; 34(1):99. PubMed ID: 11959204
    [No Abstract]   [Full Text] [Related]  

  • 37. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.
    Hong JC; Kahan BD
    Transplantation; 2000 May; 69(10):2085-90. PubMed ID: 10852601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
    Celik S; Doesch A; Erbel C; Blessing E; Ammon K; Koch A; Katus HA; Dengler TJ
    Transplantation; 2008 Jul; 86(2):245-50. PubMed ID: 18645486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study.
    McCune TR; Thacker LR II; Peters TG; Mulloy L; Rohr MS; Adams PA; Yium J; Light JA; Pruett T; Gaber AO; Selman SH; Jonsson J; Hayes JM; Wright FH; Armata T; Blanton J; Burdick JF
    Transplantation; 1998 Jan; 65(1):87-92. PubMed ID: 9448150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
    Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
    J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.